A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)

Dedifferentiated liposarcomas (DDLPS) are aggressive soft tissue sarcomas with no effective medical treatment options. Immunotherapy with checkpoint inhibitors, so-called PD-1 inhibitors, have shown some effect in DDLPS in previous studies. Effect of immunotherapy can be improved by combining it with other types of tumor drugs. Medicines that inhibit signaling via the FGF receptor, so-called FGFR inhibitors, have shown a tumor-slowing effect in DDLPS in early studies. FGFR inhibitors can also induce changes that make the tumor more available to treatment with immunotherapy. The study aims to

Trial Details

NCT ID
NCT06389799
Phase
PHASE2
Sponsor
Lund University Hospital
Status
RECRUITING
Cancer Type
Liposarcoma Sarcoma
Interventions
  • Pemigatinib
  • Retifanlimab
Locations (sample)
  • Oslo, Norway|59.91273,10.74609
  • Gothenburg, Sweden|57.70716,11.96679
  • Lund, Sweden|55.70584,13.19321
  • Stockholm, Sweden|59.32938,18.06871

Key Eligibility Criteria

  • Participants will be eligible for the study if all of the following criteria are met:
  • Be 18 years of age or above, on day of signing informed consent.
  • Must be willing and able to provide written informed consent. Written informed consent must be signed and dated before the start of specific protoc…
  • Must be willing and able to conform to and comply with all protocol requirements, including, all scheduled visits, protocol procedures, and the abi…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liposarcoma Sarcoma Trials on Trialify →